MapLight Therapeutics Gains from Bristol Myers’ ADEPT-2 Study Update

MapLight Therapeutics sees upside as Bristol Myers continues ADEPT-2 Alzheimer’s psychosis trial despite site irregularities, with potential catalysts for 2026.